Nothing Special   »   [go: up one dir, main page]

WO2021186458A1 - 6-oxo-3-phenylpyridazine based cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases - Google Patents

6-oxo-3-phenylpyridazine based cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases Download PDF

Info

Publication number
WO2021186458A1
WO2021186458A1 PCT/IN2021/050041 IN2021050041W WO2021186458A1 WO 2021186458 A1 WO2021186458 A1 WO 2021186458A1 IN 2021050041 W IN2021050041 W IN 2021050041W WO 2021186458 A1 WO2021186458 A1 WO 2021186458A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenylpyridazin
thiazol
oxo
benzylidene
methyl
Prior art date
Application number
PCT/IN2021/050041
Other languages
French (fr)
Inventor
Abida
Anupama Diwan
Hamdy K. THABET
Imran Mohd.
Md. Afroz BAKHT
Original Assignee
Abida
Anupama Diwan
Thabet Hamdy K
Mohd Imran
Bakht Md Afroz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abida, Anupama Diwan, Thabet Hamdy K, Mohd Imran, Bakht Md Afroz filed Critical Abida
Publication of WO2021186458A1 publication Critical patent/WO2021186458A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ; Het is selected from the formula II, III, and
  • 3 ⁇ 4 is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • Emorfazone an analgesic and anti-inflammatory pyridazine derivative
  • pyridazine derivatives have emerged as a novel prototype for developing non-ulcerogenic cyclooxygenase-2 (COX-2) inhibitory anti-inflammatory agents (Singh et al, Future Medicinal Chemistry, 2017, 9(1), p. 95-127).
  • the generation of the COX-2 is responsible for the development of inflammatory events in a cell, which ultimately leads to the development of inflammatory diseases, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis (Chen et al, Oncotarget, 2017, 9(6), p. 7204-7218; Varela et al, Inflammation, 2018, 41(4), p. 1115-1127).
  • inflammatory diseases for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis (Chen et al, Onco
  • the COX-2 inhibitors may be used to treat diseases associated with the higher activity of the COX- 2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • diseases associated with the higher activity of the COX- 2 for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • U.S. Patent No. 4,404,203 provides the preparation of critical intermediates, for example, 6-phenyl-4,5-dihydropyridazin-3(2H)-one and 6-phenylpyridazin-3(2H)- one.
  • the primary objective of the present invention is to provide novel 6-oxo-3-phenylpyridazine based cyclooxygenase -2 (COX-2) inhibitors of formula I, which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • COX-2 6-oxo-3-phenylpyridazine based cyclooxygenase -2
  • the present inventors have identified novel 6-oxo-3- phenylpyridazine based COX-2 inhibitors of formula I, which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • diseases associated with the higher activity of the COX-2 for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ;
  • Het is selected from the formula II, III, and
  • Ri is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • novel 6-oxo-3- phenylpyridazine based COX-2 inhibitors of formula I which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • the present invention provides a compound of formula I,
  • R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ; Het is selected from the formula II, III, and IV,
  • R is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • the present invention provides a compound of formula V, v
  • R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ;
  • R is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • the present invention provides a compound of formula VI,
  • R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ;
  • R is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • the present invention provides a compound of formula VII, [028] wherein, R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N0 2 , -CH 3 , and -C 2 H 5 ; R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
  • the present invention provides a compound selected from the group of
  • the present invention provides a compound selected from the group of [042] 2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazineyl)-5-(2-oxoindolin-3-ylidene)thiazol-4(5H)-one
  • the present invention provides a compound selected from the group of [047] 6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one, and [048] 2-(4-((2-(4-(4-Bromophenyl)thiazol-2- yl)hydrazineylidene)methyl)phenyl) -6-phenylpyridazin-3 (2H) -one . [049] In the ninth aspect, the present invention provides a compound selected from the group of [047] 6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one, and [048] 2-(4-((2-(4-(4-Bromophenyl)thiazol-2- yl)hydr
  • the present invention provides a compound 5-(4-Methoxybenzylidene)-2-(2-(4-(6-oxo-3- phenylpyridazin-l(6H)-yl)benzylidene)hydra-zineyl)thiazol-4(5H)-one
  • novel 6-oxo-3-phenylpyridazine based cyclooxygenase-2 (COX-2) inhibitors of formula I may be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • the compounds of formula V for example, 2-(4-((2-(4-(4- fluorophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)-6-phenylpyridazin- 3(2H)-one; 2-(4-((2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazono)methyl) phenyl)-6-phenylpyridazin-3(2H)-one; and 2-(4-((2-(4-(4-iodophenyl) thiazol-2-yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3(2H)-one can be prepared by following the example 4 and example 5 by using appropriate substituted phenacyl bromide.
  • Example 9 In vitro COX-1 & COX-2 inhibition assay [076] The compounds 4, 5, 7, and 8 were subjected to the COX-1 &
  • COX-2 inhibition assay using assay kits of the human COX-1 & COX-2, which was obtained from Cayman Chemicals (560131, Ann Arbor, MI, USA). The kit supplier’s instructions were followed to carry out the COX- 1 & COX-2 inhibition assay. The result is provided in the following Table 1.
  • These compounds can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
  • diseases associated with the higher activity of the COX-2 for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a compound of formula I, (I) wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, and -C2H5; Het is selected from the formula II, III, and IV, (II) (III) IV) wherein R1 is selected from the group consisting of –F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.

Description

[002] TITLE OF INVENTION
[003] 6-Oxo-3-Phenylpyridazine Based Cyclooxygenase-2 Inhibitors for the Treatment of Inflammatory Diseases
[004] Technical field of the invention:
[005] The present invention provides a compound of formula I,
Figure imgf000002_0001
[006] wherein R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; Het is selected from the formula II, III, and
Figure imgf000002_0002
[007] wherein ¾ is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
[008] Background of the invention:
[009] Pyridazine, a famous diazine ring, is part of many pharmacodynamic agents (Khalil el al, Bioorganic & Medicinal Chemistry, 2014, 22(7), p. 2080-2089; Saeed et al. , Archives ofPharmacal Research, 2012, 35(12), p. 2077-2092; Bingham et al, Journal of Pharmacology & Experimental Therapeutics, 2005, 312(3), p. 1161-1169; Ahmed et al, European Journal of Medicinal Chemistry, 2019, 171, p. 25- 37). Emorfazone (Pentoil), an analgesic and anti-inflammatory pyridazine derivative, is in clinical use in Japan and is claimed to lack gastric side effects (Singh et al, Future Medicinal Chemistry, 2017, 9(1), p. 95- 127). Recently, pyridazine derivatives have emerged as a novel prototype for developing non-ulcerogenic cyclooxygenase-2 (COX-2) inhibitory anti-inflammatory agents (Singh et al, Future Medicinal Chemistry, 2017, 9(1), p. 95-127). The generation of the COX-2 is responsible for the development of inflammatory events in a cell, which ultimately leads to the development of inflammatory diseases, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis (Chen et al, Oncotarget, 2017, 9(6), p. 7204-7218; Varela et al, Inflammation, 2018, 41(4), p. 1115-1127). Accordingly, the COX-2 inhibitors may be used to treat diseases associated with the higher activity of the COX- 2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
[010] U.S. Patent No. 4,404,203 provides the preparation of critical intermediates, for example, 6-phenyl-4,5-dihydropyridazin-3(2H)-one and 6-phenylpyridazin-3(2H)- one.
[Oil] Objective:
[012] The primary objective of the present invention is to provide novel 6-oxo-3-phenylpyridazine based cyclooxygenase -2 (COX-2) inhibitors of formula I, which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
[013] Summary of the invention:
[014] The present inventors have identified novel 6-oxo-3- phenylpyridazine based COX-2 inhibitors of formula I, which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
[015] The present invention provides a compound of formula I,
Figure imgf000004_0001
[016] wherein R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; Het is selected from the formula II, III, and
IV,
Figure imgf000005_0001
[017] wherein Ri is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
[018] Detailed description of the invention: [019] The present inventors have identified novel 6-oxo-3- phenylpyridazine based COX-2 inhibitors of formula I, which can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
[020] In the first aspect, the present invention provides a compound of formula I,
Figure imgf000005_0002
[021] wherein R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; Het is selected from the formula II, III, and IV,
Figure imgf000005_0003
[022] wherein R, is selected from the group consisting of -F, -Cl, - Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
[023] In the second aspect, the present invention provides a compound of formula V,
Figure imgf000006_0001
v
[024] wherein R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; R is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy. [025] In the third aspect, the present invention provides a compound of formula VI,
Figure imgf000006_0002
[026] wherein R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy. [027] In the fourth aspect, the present invention provides a compound of formula VII,
Figure imgf000006_0003
[028] wherein, R is selected from the group consisting of -H, -F, -Cl, - Br, -I, -N02, -CH3, and -C2H5; R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
[029] In the fifth aspect, the present invention provides a compound selected from the group of
[030] 6-Phenyl-2-(4-((2-(4-phenylthiazol-2-yl)hydrazinylidene)methyl) phenyl) pyridazin-3(2H)-one
[031] 2-(4-((2-(4-(4-Bromophenyl)thiazol-2- yl)hydrazineylidene)methyl)phenyl)-6- phenylpyridazin-3(2H)-one [032] 2-(4-((2-(4-(4-fluorophenyl)thiazol-2- yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3 (2H)-one [033] 2-(4-((2-(4-(4-chlorophenyl)thiazol-2- yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3 (2H)-one, and [034] 2-(4-((2-(4-(4-iodophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)- 6-phenylpyridazin-3 (2H)-one [035] In the sixth aspect, the present invention provides a compound selected from the group of
[036] 5 -(4-Chlorobenzylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)- hydra-zinyl)thiazol-4(5H)-one [037] 5 -(4-Methoxybenzylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin - 1(6H)- yl)benzylidene)hydra-zineyl)thiazol-4(5H)-one
[038] 5 -(4-fluorobenzylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
[039] 5-(4-bromobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one, and [040] 5 -(4-iodobenzylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one [041] In the seventh aspect, the present invention provides a compound selected from the group of [042] 2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazineyl)-5-(2-oxoindolin-3-ylidene)thiazol-4(5H)-one
[043] 5 -(5 -fluoro-2-oxoindolin-3 -ylidene)-2-(2-(4-(6-oxo-3 - phenylpyridazin- 1(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one [044] 5-(5-chloro-2-oxoindolin-3-ylidene)-2-(2-(4-(6-oxo-3- phenylpyridazin- 1(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one, and [045] 5-(5-methyl-2-oxoindolin-3-ylidene)-2-(2-(4-(6-oxo-3- phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
[046] In the eighth aspect, the present invention provides a compound selected from the group of [047] 6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one, and [048] 2-(4-((2-(4-(4-Bromophenyl)thiazol-2- yl)hydrazineylidene)methyl)phenyl) -6-phenylpyridazin-3 (2H) -one . [049] In the ninth aspect, the present invention provides a compound
2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)-yl)benzylidene)hydrazineyl)-5 - (2-oxoindolin-3- ylidene)thiazol-4(5H)-one
[050] In the tenth aspect, the present invention provides a compound 5-(4-Methoxybenzylidene)-2-(2-(4-(6-oxo-3- phenylpyridazin-l(6H)-yl)benzylidene)hydra-zineyl)thiazol-4(5H)-one
[051] The novel 6-oxo-3-phenylpyridazine based cyclooxygenase-2 (COX-2) inhibitors of formula I may be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.
[052] The method of preparation of some compounds of the present invention has been exemplified in example 4, example 5, example 7, and example 8. The process of preparing 6-phenylpyridazin-3(2H)-one is provided in U.S. Patent No. 4,404,203. The method of preparation of other intermediates is provided in example 1, example 2, and example 6. The COX-2 inhibitory activity of the compounds 4, 5, 7, and 8 is exemplified in example 9.
[053] While the present invention has been described in terms of its specific embodiments and examples, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
[054] EXAMPLES
[055] Example 1: Synthesis of 4-(6-Oxo-3-phenylpyridazin- l(6/7)yl)benzaldehyde (1)
Figure imgf000009_0001
[056] A mixture of 6-phenylpyridazin-3(2H)-one (10 mmoles), p- fluorobenzaldehyde (10 mmoles), anhydrous K2C03 (10 mmoles) in dimethylsulfoxide (40 mL) was heated to 100°C for 5 hours, and discharged in the crushed ice. The fdtered solid was recrystallized from ethanol m.p: 187-189°C; ½-NMR (500 MHz, DM SO A, d in ppm): 7.14 (d, 1H, Ar-H), 7.43 (brs, 3H, Ar-H), 7.88 (m, 3H, Ar-H), 7.99 (brs,
3H, Ar-H), 8.12 (d, 1H, Ar-H), 10.01 (s, 1H, -CHO); 13C-NMR(125 MHz, DMSO-£¾ d in ppm): 126.50 (2C), 126.59, 128.13, 128.61, 129.45
(2C), 130.26, 131.78, 132.37, 134.41, 135.56, 145.22, 146.55, 154.17, 159.11, 192.85.
[057] Example 2: Synthesis of 2-(4-(6-Oxo-3-phenyl pyridazin-l(6H)-yl)benzylidene)hydrazine-l-carbothioamide (2)
Figure imgf000010_0001
[058] The mixture of compound 1 (10 mmoles), thiosemicarbazide (10 mmoles), and acetic acid (40 mL) was heated to 125°C for 3 hours to acquire a precipitate. The fdtered precipitate was recrystallized from dioxane to get the compound m.p: 235-237°C; ^H-NMR (500 MHz, DMSO- d in ppm): 7.18 (d, 1H, Ar-H), 7.49 (brs, 3H, Ar-H), 7.74 (d, 2H, Ar-H), 7.94 (m, 4H, Ar-H), 8.12 (m, 3H, Ar-H + NH2), 8.25 (s, 1H, azomethine-H), 11.52 (s, 1H, NH); 13C-NMR(125 MHz, DMSO-A, d in ppm): 126.14, 126.54 (2C), 127.89 (2C), 128.57 (2C), 129.43 (2C), 129.65, 129.72, 131.54, 134.61, 142.94, 144.85, 159.08, 160.73, 178.61.
[059] Example 3: Synthesis of 2-(4-(6-Oxo-3-phenylpyridazin-l(6/7)- yl)benzylidene)-N-phenylhydrazine-l-carbothioamide (3)
Figure imgf000011_0001
[060] The mixture of compound 1 (10 mmoles), 2-phenylhydrazine-l- carbothioamide (10 mmoles), and acetic acid (40 mL) was heated to
125°C for 3 hours to acquire a precipitate. The filtered precipitate was recrystallized from dioxane to get the compound m.p: 247-249°C; * H- NMR (500 MHz, DMSO-£/6, d in ppm): 7.15 (d, 2H, Ar-H), 7.37, 7.46, 7.59 (3brs , 7H, Ar-H), 7.75, 7.88 (2brs, 4H, Ar-H), 8.05 (brs, 3 H, Ar-H), 8.23 (s, 1H, azomethine-H), 10.19 & 11.93 (2s, 2H, 2NH); 13C-
NMR(125MHz, DMSO-£/6, d in ppm): 125.91 (2C), 126.11 (2C), 126.37, 126.50, 128.21, 128.58 (2C), 129.42 (2C), 130.12, 131.48, 131.57, 132.33, 134.03, 134.53, 139.44, 142.32, 143.06, 144.90, 154.26, 159.14, 176.55.
[061] Example 4: Synthesis of 6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one (4)
Figure imgf000011_0002
[062] A mixture of compound 2 (10 mmoles), 2-bromo-l-phenylethan-l- one (10 mmoles) and sodium acetate (20 mmoles) in acetic acid (30 mL) was refluxed for 4 hours. The solid produced was collected and purified from dioxane. m.p. 280-281°C; 1 H-NMR (500 MHz, DM SO- A, d in ppm): 7.04-7.50 (m, 9H, Ar-H + thiazole-H), 7.79-8.11 (m, 9H, Ar-H + azomethine-H), 12.28 (s, 1H, NH); 13C-NMR(125 MHz, DMSO-A, d in ppm): 168.60, 159.07, 144.82, 142.46, 140.67, 135.13, 134.64, 134.44, 132.37, 131.60, 131.52, 130.10, 129.43, 129.08 (2C), 128.02 (2C), 126.79
(2C), 126.55 (2C), 126.34 (2C), 126.0 (2C), 104.33.
Figure imgf000012_0001
[063] Example 5: Synthesis of 2-(4-((2-(4-(4-Bromophenyl)thiazol-2- yl)hydrazineylidene)-methyl)phenyl)-6-phenylpyridazin-3(2H)-one (5)
[064] A mixture of compound 2 (10 mmoles), 2-bromo-l-(4- bromophenyl)ethan-l-one (10 mmoles) and sodium acetate (20 mmoles) in acetic acid (30 mL) was refluxed for 4 hours. The solid produced was collected and purified from dioxane. m.p. 261 -262°C: * H-NMR (500
MHz, DMSO-A, d in ppm): 7.20-8.33 (m, 17H, Ar-H + thiazole-H5
+azomethine-H), 12.31 (s, 1H, NH); 13C-NMR(125 MHz, DMSO-A, d in ppm): 168.78, 159.08, 149.92, 144.83, 142.53, 141.64, 140.87, 134.66, 134.36, 132.02, 131.62, 131.51, 130.11, 129.44, 128.59 (2C), 128.04, 127.91 (2C), 126.84, 126.57 (2C), 126.34, 126.15, 121.03, 105.24.
[065] The compounds of formula V, for example, 2-(4-((2-(4-(4- fluorophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)-6-phenylpyridazin- 3(2H)-one; 2-(4-((2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazono)methyl) phenyl)-6-phenylpyridazin-3(2H)-one; and 2-(4-((2-(4-(4-iodophenyl) thiazol-2-yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3(2H)-one can be prepared by following the example 4 and example 5 by using appropriate substituted phenacyl bromide.
[066] Example 6: Synthesis of 2-(2-(4-(6-Oxo-3- phenylpyridazin-l(6H)- yl)benzylidene)hydrazineyl)thiazol-4(5H)-one
(6)
Figure imgf000013_0001
[067] A mixture of compound 2 (10 mmoles), ethyl 2-chloroacetate (10 mmoles) and sodium acetate (20 mmoles) in acetic acid (30 mL) was refluxed for 4 hours. The solid produced was collected and purified from dioxane.
Figure imgf000013_0002
ppm): 3.92 (s, 2H, -S-CH2-), 7.20 (d, 2H, Ar-H), 7.48 (q,3H, Ar-H), 7.80 (d, 2H, Ar-H), 7.89 (d, 2H, Ar-H), 8.14 (d, 2H, Ar-H), 8.48 (s, 1H, azomethine-H), 12.12
Figure imgf000013_0003
ppm): 170.43, 159.06, 155.87, 154.58, 144.88, 143.59, 134.57, 134.15, 131.64, 130.14 (2C), 129.43 (2C), 128.25 (2C), 126.56 (2C), 126.34 (2C),
33.54.
[068] Example 7: Synthesis of 5-(4-Methoxy benzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)-yl)benzylidene) hydrazineyl)thiazol-4(5H)-one (7)
Figure imgf000014_0001
[069] A mixture of compound 6 (10 mmoles), and 4- methoxybenzaldehyde (10 mmoles) and piperidine (0.5 mL) in dioxane (30 mL) was refluxed for 3 to 6 hours. The solid produced was collected and purified using dioxane. m.p. > 300°C; ^H-NMR (500MHz, DMSO-£¾ d in ppm): 3.91 (s, 3H, OCH3), 6.94 (d, 2H, Ar-H), 7.24 (d, 2H, Ar- H), 7.50-7.58 (2brs, 5H, Ar-H), 7.80-8.12 (3brs, 6H, Ar-H+ CH-benzylidene), 8.18 (d, 1H, Ar-H), 8.50 (s, 1H, azomethine-H), 11.12 (s, 1H, NH); 13C-NMR(125 MHz, DMSO-ri6, d in ppm): 168.27, 166.11,
165.48, 159.09, 155.46, 155.17, 144.76, 134.65, 131.61 (2C), 130.98 (2C), 130.11 (2C), 129.44 (3C), 129.16 (3C), 127.21 (2C), 126.55 (3C), 126.16 (2C), 55.68. [070] The compounds of formula VI, for example, 5-(4-
Chlorobenzylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)-hydra-zinyl)thiazol-4(5H)-one ; 5 -(4- fluorobenzybdene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one; 5-(4- bromobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin- 1(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one; and 5-(4- iodobenzylidene)- 2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)-yl)benzylidene)hydrazinyl) thiazol-4(5H)-one can be prepared by following the example 7 using appropriate substituted benzaldehyde. [071] Example 8: Synthesis of 2-(2-
(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazineyl)-5-(2- oxoindolin-3-ylidene)thiazol-4(5H)-one (8)
Figure imgf000015_0001
[072] A mixture of 6 (10 mmoles), indoline-2,3-dione (10 mmoles) and piperidine (0.5 mL) was refluxed in dioxane (30 mL) for 2 hours. The solid was filtered hot, washed with ethanol, and purified with dioxane.
Figure imgf000015_0002
ppm): 6.76 (d, 1H,
Ar-H), 6.93 (d, 1H, Ar-H), 7.05 (d, 2H, Ar-H), 7.22 (d, 2H,Ar-H), 7.50 (brs, 3H, Ar-H), 7.87, 7.92 (2brs, 5H, Ar-H), 8.18 (d, 1H, Ar-H), 8.36
(s,lH, azomethine-H), 11.20, 12.51 (2s, 2H, 2NH); 13C-NMR(125 MHz, DMSO-£/6, d in ppm): 175.43, 168.22, 161.15, 159.53, 159.23, 157.51, 155.34, 145.12, 143.60, 134.58, 134.38, 132.33, 132.24, 131.68, 130.29,
129.48 (2C), 129.14 (2C), 128.71 (2C), 126.67 (3C), 126.22 (2C), 122.14, 121.92.
[073] The compounds of formula VII, for example, 5-(5-fluoro-2- oxoindolin-3-ylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)-yl) benzylidene)hydrazinyl)thiazol-4(5H)-one;
[074] 5-(5-chloro-2-oxoindolin-3-ylidene)-2-(2-(4-(6-oxo-3- phenylpyridazin-l(6H)-yl)benzylidene)hydrazinyl)thiazol-4(5H)-one; and 5 -(5 -methyl-2-oxoindolin-3 - ylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- l(6H)-yl)benzybdene)hydrazinyl)thiazol-4(5H)-one can be prepared by following the example 8 using appropriate substituted isatin.
[075] Example 9: In vitro COX-1 & COX-2 inhibition assay [076] The compounds 4, 5, 7, and 8 were subjected to the COX-1 &
COX-2 inhibition assay using assay kits of the human COX-1 & COX-2, which was obtained from Cayman Chemicals (560131, Ann Arbor, MI, USA). The kit supplier’s instructions were followed to carry out the COX- 1 & COX-2 inhibition assay. The result is provided in the following Table 1.
[077] Table 1: In vitro COX-1 & COX-2 inhibition (N = 3, Mean ± SD)
Figure imgf000016_0001
[078] *All values had p < 0.5 (SPSS software); SI: IC50 for COX-1 in nM / IC 50 for COX-2 in mpi. [079] The in vitro COX-1 & COX-2 inhibition assay results indicate that compounds 4, 5, 7, and 8 have better COX-2 inhibitory activity than celecoxib and indomethacin. These compounds can be used to treat diseases associated with the higher activity of the COX-2, for example, gout, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, ulcerative colitis, depression, epilepsy, irritable bowel diseases, kidney injury, cancer, asthma, hepatitis, pancreatitis, and atherosclerosis.

Claims

CLAIMS We Claim:
1. A compound of formula I,
Figure imgf000017_0003
wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -N02, - CH3, and -C2H5; Het is selected from the formula II, III, and IV,
Figure imgf000017_0001
wherein R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
2. A compound of formula V,
Figure imgf000017_0002
v wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -N02, - CH3, and -C2H5; R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
3. A compound of formula VI,
Figure imgf000018_0001
wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -N02, - CH3, and -C2H5; R, is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
4. A compound of formula VII,
Figure imgf000018_0002
wherein, R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -N02, - CH3, and -C2H5; R| is selected from the group consisting of -F, -Cl, -Br, -I, methyl, ethyl, propyl, methoxy, ethoxy, and propoxy.
5. A compound selected from the group of 6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one 2-(4-((2-(4-(4-Bromophenyl)thiazol-2-yl)hydrazineylidene)methyl)phenyl)-6- phenylpyridazin-3(2H)-one
2-(4-((2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3(2H)-one
2-(4-((2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3(2H)-one, and
2-(4-((2-(4-(4-iodophenyl)thiazol-2-yl)hydrazono)methyl)phenyl)-6- phenylpyridazin-3 (2H)-one
6. A compound selected from the group of
5-(4-Chlorobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)- hydra-zinyl)thiazol-4(5H)-one
5-(4-Methoxybenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydra-zineyl)thiazol-4(5H)-one
5-(4-fluorobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
5-(4-bromobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one, and
5-(4-iodobenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
7. A compound selected from the group of
2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)-yl)benzylidene)hydrazineyl)-5-(2- oxoindobn-3-ylidene)thiazol-4(5H)-one
5-(5-fluoro-2-oxoindolin-3-ylidene)-2-(2-(-4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
5-(5-chloro-2-oxoindolin-3-ylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin-l(6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one, and
5 -(5 -methyl -2-oxoindolin-3 -ylidene)-2-(2-(4-(6-oxo-3 -phenylpyridazin- 1 (6H)- yl)benzylidene)hydrazinyl)thiazol-4(5H)-one
8. A compound selected from the group consisting of
6-Phenyl-2-(4-((2-(4-phenylthiazol-2- yl)hydrazinylidene)methyl)phenyl)pyridazin-3(2H)-one, and 2-(4-((2-(4-(4-Bromophenyl)thiazol-2-yl)hydrazineylidene)methyl)phenyl)-6- phenylpyridazin-3(2H)-one
9. A compound 2-(2-(4-(6-oxo-3- phenylpyridazin- 1 (6H)-yl)benzylidene)hydrazineyl)-5 -(2-oxoindolin-3 - ylidene)thiazol-4(5H)-one
10. A compound 5-(4-Methoxybenzylidene)-2-(2-(4-(6-oxo-3-phenylpyridazin- l(6H)-yl)benzylidene)hydra-zineyl)thiazol-4(5H)-one
Figure imgf000020_0001
Dr. Amrish Chandra Agent of the applicant IN/PA No: 2959
PCT/IN2021/050041 2020-03-19 2021-01-16 6-oxo-3-phenylpyridazine based cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases WO2021186458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202011012010 2020-03-19
IN202011012010 2020-03-19

Publications (1)

Publication Number Publication Date
WO2021186458A1 true WO2021186458A1 (en) 2021-09-23

Family

ID=77771684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050041 WO2021186458A1 (en) 2020-03-19 2021-01-16 6-oxo-3-phenylpyridazine based cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases

Country Status (1)

Country Link
WO (1) WO2021186458A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KHAN ABIDA, DIWAN ANUPAMA, THABET HAMDY K, IMRAN MOHD: "Synthesis of novel N‐substitutedphenyl‐6‐oxo‐3‐phenylpyridazine derivatives as cyclooxygenase‐2 inhibitors", DRUG DEVELOPMENT RESEARCH, vol. 81, no. 5, 1 August 2020 (2020-08-01), US , pages 573 - 584, XP055860216, ISSN: 0272-4391, DOI: 10.1002/ddr.21655 *

Similar Documents

Publication Publication Date Title
EP2440550B1 (en) Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
US20040097566A1 (en) 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
JP5734532B2 (en) Azolbenzene derivatives
CN1285821A (en) Aryl Fused azapolycyclic compounds
EP0433149B1 (en) Serotonin antagonists, their preparation and pharmaceuticals containing them
MX2011003191A (en) Phenethylamide derivatives and their heterocyclic analogues.
JP2008539183A (en) Oxazole and thiazole compounds and their use in the treatment of PGE2-mediated disorders
CN1059210C (en) 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz {cd} indoles
JP2012502006A5 (en)
CN1443180A (en) Novel compounds having antiinflamatory activity process for their preparation and pharmaceutical compositions containing them
TW200932742A (en) Activator for peroxisome proliferator activated receptor
AU2007265965B2 (en) Pyridylisoxazole derivative
JP2008546839A (en) Non-nucleoside reverse transcriptase inhibitors
WO2021186458A1 (en) 6-oxo-3-phenylpyridazine based cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases
CA1330341C (en) Imidazole derivatives ii
HUT62888A (en) Process for producing new oxazole derivatives and pharmaceutical compositions comprising same
CN86103071A (en) The preparation method of antipsychotic fused-ring pyridinypiperazine derivatives
AU2005320544B2 (en) Pyrimidinylisoxazol derivative
PL171273B1 (en) Method of obtaining novel derivatives of tridiazinones
Şerban et al. Synthesis of some 2-R-5-formyl-1, 3, 4-thiadiazole derivatives by Sommelet reaction
WO2002092593A1 (en) 4-(4-pyridazinyl)pyrazole derivatives
EP2448932A1 (en) Novel 6-morpholin-4-yl-pyrimidin-4-(3h)-one derivatives, and the pharmaceutical preparation thereof as akt(pkb) phosphorylation inhibitors
WO2021124344A1 (en) Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors
WO2016017699A1 (en) Azole carboxylic acid derivative
JP2008509201A (en) Mercaptoimidazoles as CCR2 receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21771690

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21771690

Country of ref document: EP

Kind code of ref document: A1